Der Urologe, Ausgabe A

, Volume 44, Issue 2, pp 151–154 | Cite as

Harnblasenkarzinom

Konservative oder operative Therapie bei PT1G3
Übersichten

Zusammenfassung

Da prospektiv randomisierte Studien zu Therapie und Outcome bei T1G3-Harnblasenkarzinom fehlen, ist ein Therapieentscheid nur anhand retrospektiver Studien oder mit Hilfe der individuellen Erfahrung des einzelnen Urologen möglich. Im Folgenden werden die Vor- und Nachteile der primären Zystektomie sowie der transurethralen Resektion alleine bzw. in Kombination mit BCG-Instillationstherapie dargestellt und verglichen.

Schlüsselwörter

T1G3-Harnblasenkarzinom Primäre radikale Zystektomie Transurethrale Resektion BCG-Instillationstherapie 

Carcinoma of the urinary bladder

Conservative or surgical treatment in pT1G3 disease

Abstract

As no prospective randomised studies are available on therapy and outcome in T1G3 carcinoma of the urinary bladder, a decision on therapy can only be made on the basis of retrospective studies or with reference to the individual experience of a particular urologist. In this paper the advantages and disadvantages of primary cystectomy and of transurethral resection, both alone and in combination with BCG instillation, are discussed and compared.

Keywords

T1G3 carcinoma of the urinary bladder Primary radical cystectomy Transurethral resection BCG instillation 
This is a preview of subscription content, log in to check access.

Notes

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Literatur

  1. 1.
    Cookson MS, Herr HW, Zhang ZF et al. (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158: 62–67CrossRefGoogle Scholar
  2. 2.
    Dave SS, Wright G, Tan B et al. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351: 2159–2169CrossRefGoogle Scholar
  3. 3.
    Hautmann RE, Petriconi R de, Gottfried HW et al. (1999) The ileal neobladder: complications and functional results in 363 patients after 11 years of followup. J Urol 161: 422–428CrossRefPubMedGoogle Scholar
  4. 4.
    Herr HW (1997) Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome. Br J Urol 80: 762–765Google Scholar
  5. 5.
    Hunter KW (2004) Host genetics and tumour metastasis. Br J Cancer 90: 752–725CrossRefGoogle Scholar
  6. 6.
    Jakse G, Loidl W, Seeber G et al. (1987) Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 137: 39–43Google Scholar
  7. 7.
    Klaen R, Miller K (1998) Radikale Zystektomie beim T1G3-Harnblasenkarzinom—oft zu früh? Akt Urol 29: 65–69Google Scholar
  8. 8.
    Lamm DL, Blumenstein BA, Crissman JD et al. (2000) Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163: 1124–1129CrossRefPubMedGoogle Scholar
  9. 9.
    Paik S, Shak S, Tang G et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817–2826CrossRefGoogle Scholar
  10. 10.
    Patard JJ, Rodriguez A, Leray E et al. (2002) Intravesical bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 41: 635–642CrossRefGoogle Scholar
  11. 11.
    Peyromaure M, Weibing S, Sebe P et al. (2002) Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 59: 409–413CrossRefGoogle Scholar
  12. 12.
    Shahin O, Thalmann GN, Rentsch C et al. (2003) A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169: 96–100CrossRefGoogle Scholar
  13. 13.
    Stockle M, Alken P, Engelmann U et al. (1987) Radical cystectomy — often too late? Eur Urol 13: 361–367Google Scholar
  14. 14.
    Sylvester RJ, Meijden AP van der, Lamm DL (2002) Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168: 1964–1970CrossRefPubMedGoogle Scholar
  15. 15.
    Thalmann GN, Markwalder R, Shahin O et al. (2004) Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 172: 70–75CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag 2005

Authors and Affiliations

  1. 1.Urologische KlinikCharité, Campus Benjamin FranklinBerlin
  2. 2.Urologische KlinikUniversitätsklinikum Ulm
  3. 3.Urologische KlinikCharité, Campus Benjamin FranklinBerlin

Personalised recommendations